AU7176094A - Method for treating hyperkeratosis and diseases mediated by proteases - Google Patents

Method for treating hyperkeratosis and diseases mediated by proteases

Info

Publication number
AU7176094A
AU7176094A AU71760/94A AU7176094A AU7176094A AU 7176094 A AU7176094 A AU 7176094A AU 71760/94 A AU71760/94 A AU 71760/94A AU 7176094 A AU7176094 A AU 7176094A AU 7176094 A AU7176094 A AU 7176094A
Authority
AU
Australia
Prior art keywords
acid
acetylcysteine
group
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU71760/94A
Other languages
English (en)
Inventor
Kenneth A. Arndt
Stephen J. Galli
Maureen H McAloon
Richard J Sharpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcturus Pharmaceutical Corp
Original Assignee
Arcturus Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/131,892 external-priority patent/US5637616A/en
Application filed by Arcturus Pharmaceutical Corp filed Critical Arcturus Pharmaceutical Corp
Publication of AU7176094A publication Critical patent/AU7176094A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU71760/94A 1993-06-18 1994-06-20 Method for treating hyperkeratosis and diseases mediated by proteases Abandoned AU7176094A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US7964593A 1993-06-18 1993-06-18
US079645 1993-06-18
US10261793A 1993-08-05 1993-08-05
US102617 1993-08-05
US131892 1993-10-05
US08/131,892 US5637616A (en) 1993-06-18 1993-10-05 Method for treating diseases mediated by proteases
US14786493A 1993-11-04 1993-11-04
US147864 1993-11-04
PCT/US1994/006949 WO1995000136A1 (en) 1993-06-18 1994-06-20 Method for treating hyperkeratosis and diseases mediated by proteases

Publications (1)

Publication Number Publication Date
AU7176094A true AU7176094A (en) 1995-01-17

Family

ID=27491490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71760/94A Abandoned AU7176094A (en) 1993-06-18 1994-06-20 Method for treating hyperkeratosis and diseases mediated by proteases

Country Status (4)

Country Link
JP (1) JPH11501611A (ja)
AU (1) AU7176094A (ja)
CA (1) CA2164955A1 (ja)
WO (1) WO1995000136A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681852A (en) * 1993-11-12 1997-10-28 The Procter & Gamble Company Desquamation compositions
AU704481B2 (en) * 1994-06-23 1999-04-22 Textile Research Institute Inc Topical compositions comprising N-acetyl-L-cysteine
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
SE9601527D0 (sv) 1996-04-23 1996-04-23 Pharmacia Ab Transdermally alministered acetylcysteine as mucolytic agent
GB2320431B (en) * 1996-12-20 2000-08-30 Johnson & Johnson Medical Compositions for the treatment of chronic wounds
DE19819616A1 (de) * 1998-05-04 1999-11-11 Hexal Ag Verwendung von Antioxidantien zur Behandlung von entzündlichen Hauterkrankungen
EP1013178B2 (en) * 1998-12-22 2009-09-16 Unilever N.V. Cosmetic use of petroselinic acid
US6159485A (en) 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
ITMI20031941A1 (it) * 2003-10-09 2005-04-10 Sinclair Pharmaceuticals Ltd Composizioni farmaceutiche topiche per il trattamento delle dermatiti
EP2046277B1 (en) 2006-07-25 2011-01-19 ZAMBON S.p.A. Cosmetic or dermatological preparations comprising n-acetylcysteine
ES2336995B1 (es) 2008-10-13 2011-02-09 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica para el cuidado de la piel,cuero cabelludo y uñas.
GB2470040A (en) 2009-05-06 2010-11-10 Systagenix Wound Man Ip Co Bv Wound dressing material comprising N-acetyl cysteine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2519988B1 (fr) * 1982-01-20 1985-06-14 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
IT1194117B (it) * 1981-11-20 1988-09-14 Isnardi Pietro & C Spa Derivati salicilici di n-acetilcisteina
US4414387A (en) * 1982-05-13 1983-11-08 Renato Broggi Cephapirin acetylcysteinate having antibacterial activity

Also Published As

Publication number Publication date
CA2164955A1 (en) 1995-01-05
WO1995000136A1 (en) 1995-01-05
JPH11501611A (ja) 1999-02-09

Similar Documents

Publication Publication Date Title
US5637616A (en) Method for treating diseases mediated by proteases
US5993845A (en) Anti-fibrotic medicament
CA2680843C (en) Pharmaceutical composition for treatment of diabetic complications
JP3902406B2 (ja) 老化防御効果を示すテトラペプチド、これを基にした薬理学的物質、及びその利用法
US6369106B1 (en) Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
AU7176094A (en) Method for treating hyperkeratosis and diseases mediated by proteases
EP2042167A1 (en) Use of a monoterpene to induce tissue repair
US8815836B2 (en) Use of 2,5-dihydroxybenzene derivatives for treating dermatitis
EP0750512A1 (en) A medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction
JP2016041762A (ja) 代謝性症候群を予防し又は治療するための方法
Silk et al. Comparison of oral feeding of peptide and amino acid meals to normal human subjects
CA2304622A1 (en) Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-?b via the ubiquitin proteasome pathway to treat inflammatory and autoimmunediseases
AU2001275018A1 (en) Composition and method for enhancing elasticity of tissue
CN110475474B (zh) 化合物和使用方法
Hladovec Methionine, pyridoxine and endothelial lesion in rats
KR20230084242A (ko) 피부과적 병태의 치료
KR20040094402A (ko) 랑게르한스 세포 이동을 억제하기 위한 적어도 1개의알칸올아미드를 포함하는 조성물, 및 이의 용도
Petersen Pharmacological effects of diethylthiocarbamic acid methyl ester, the active metabolite of disulfiram?
Smit et al. The relationship between plasma free fatty acids and experimentally induced hepatic encephalopathy in the rat
Cunliffe Vitamin a in Dermatology
JP2022067848A (ja) 経鼻投与用医薬組成物
Thompson et al. Effect of eflorithine on intestinal regeneration
JPH0768122B2 (ja) コラーゲンの異常蓄積を伴う疾病の治療剤
WO2008062135A1 (fr) Utilisation d'adapalène pour moduler l'expression de l'il-1ra.
Pigmentation et al. MORNING SESSION SATURDAY, 9: 00A. M.